Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218540 | 1.00 | TP53 (0.50) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL1605366 | 1.00 | TP53 (0.50) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL2554561 | 0.98 | TP53 (0.47) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL31572346 | 0.94 | THRB (0.44) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL15618893 | 0.89 | — | — | |
| SCHEMBL19941727 | 0.83 | TP53 (0.62) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL6862095 | 0.83 | TP53 (0.62) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL19942011 | 0.83 | TP53 (0.62) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL5398976 | 0.81 | TP53 (0.47) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL4491334 | 0.80 | THRB (0.61) | TP53ALDH1A1NPSR1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444254-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CDK4, CDK6, CCNI | TP53 192/4885ALDH1A1 1708/4885NPSR1 4510/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | TP53 192/4885ALDH1A1 1708/4885NPSR1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.